IL-1 Inhibitors Show No Added Pregnancy Risk

In a small French study, women with autoinflammatory diseases who took these drugs during pregnancy saw no added risk to themselves or their babies.

Updated on Nov. 20, 2026 in Children’s Health

IL-1 Inhibitors Show No Added Pregnancy Risk

Researchers reported that exposure to IL-1 inhibitor drugs during pregnancy in women with autoinflammatory diseases was not linked to increased risk for mothers or newborns in a small French study. The findings, published November 16, 2026 in RMD Open, cover 34 pregnancies in 31 women and are most relevant to women with these conditions who are pregnant or planning pregnancy.

Why it matters

Autoinflammatory diseases can flare during pregnancy, and many affected women have historically faced uncertainty about whether to continue treatment. This study adds reassuring, if limited, data on a drug class that is widely used but had little reliable pregnancy safety information.

This prospective observational study from France followed 34 pregnancies in 31 women with Still disease, familial Mediterranean fever, or cryopyrinopathy, using matched unexposed pregnant women as controls. Its small sample size means it cannot rule out rare risks, and the follow-up of exposed infants was relatively short.

The players

RMD Open

A peer-reviewed open-access journal publishing research in rheumatology and musculoskeletal diseases.

The details

IL-1 inhibitors such as anakinra and canakinumab block interleukin-1, a signaling protein central to inflammation in these conditions. In this study, 30 pregnancies were exposed to anakinra and five to canakinumab, with one exposed to both. Women were enrolled after pregnancy had already begun, and the median gestational exposure was 24.4 weeks. Outcomes were compared against matched unexposed women, and 68% of women experienced active disease flares during pregnancy.

Timeline

  1. November 16, 2026: Study published online in RMD Open.

  2. 2021: Year of the perinatal survey of 12,042 births used as a general-population comparison group.

Health Landscape

IL-1 inhibitors have become standard options for several autoinflammatory diseases, but pregnancy data for this drug class have been sparse, leaving clinicians to weigh flare risk against unknown fetal exposure. This French cohort adds structured comparative evidence to a field that has relied largely on case reports and registries.

If you have an autoinflammatory condition and are pregnant or planning pregnancy, this study offers reassuring but preliminary information about IL-1 inhibitor exposure. It is worth discussing with your rheumatologist and obstetric team, since flares during pregnancy carried significant risk in this group and treatment decisions are individual.

The takeaway

Early data suggest IL-1 inhibitors were not associated with increased maternal or neonatal risk in this small group, though larger studies are needed. Anyone with an autoinflammatory disease planning pregnancy should raise medication plans with their specialist well in advance.

Further reading

For more on how medications and health conditions intersect with early life, explore our Children’s Health coverage.

Source note: This article includes information reported by Medscape.